Literature DB >> 6995528

Quantitation of human serum very low density apolipoproteins C-I, C-II, C-III and E by enzyme immunoassay.

L Holmquist.   

Abstract

An enzyme immunoassay for human serum very low density apolipoproteins C-I, C-II, C-III and E is described. The assay is competitive and uses polystyrene tubes with adsorbed monospecific antibodies to which is added intact very low density lipoprotein (VLDL) conjugated with alkaline phosphatase. Conjugate containing all the different apolipoproteins complexed with lipids was used for quantitation of each individual aplipoprotein. The coefficients of variation were 7 and 10% for within-run and between-run reproducibility, respectively, for the range 50-100 ng apolipoprotein in the 0.5 ml sample. A comparison between apolipoprotein assays in intact and delipidated VLDL is presented.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995528     DOI: 10.1016/0022-1759(80)90051-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Subfractionation and characterization of native and incubation enlarged human plasma high density lipoprotein particles by high performance gel filtration.

Authors:  L Holmquist; L A Carlson
Journal:  Lipids       Date:  1985-06       Impact factor: 1.880

2.  Metabolism of triglyceride-rich lipoproteins during alimentary lipemia.

Authors:  F Karpe; G Steiner; T Olivecrona; L A Carlson; A Hamsten
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment.

Authors:  P Pauciullo; B De Simone; P Rubba; M Mancini
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

4.  Plasma levels of apolipoprotein-E in residents of the European North of Russia.

Authors:  Anastasiya M Kaneva; Evgeny R Bojko; Natalya N Potolitsyna; Jon O Odland
Journal:  Lipids Health Dis       Date:  2013-03-27       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.